Treatment patterns and burden of myelosuppression for patients with small cell lung cancer: A SEER-medicare study.

[1]  H. Rugo,et al.  NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  R. Epstein,et al.  Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers , 2021, Journal of medical economics.

[3]  C. Gwaltney,et al.  Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies. , 2021, Clinical lung cancer.

[4]  R. Epstein,et al.  Cancer Patients’ Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life , 2021, Patient preference and adherence.

[5]  I. Bondarenko,et al.  Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial , 2020, International journal of cancer.

[6]  J. Subramanian,et al.  Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study , 2020, Advances in Therapy.

[7]  James D. Mitchell,et al.  Remote Oncology Care: Review of Current Technology and Future Directions , 2020, Cureus.

[8]  R. Epstein,et al.  Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors , 2020, Advances in Therapy.

[9]  H. Groen,et al.  Real‐world treatment patterns and outcomes of patients with extensive disease small cell lung cancer , 2020, European journal of cancer care.

[10]  J. Warren,et al.  Updated Overview of the SEER-Medicare Data: Enhanced Content and Applications. , 2020, Journal of the National Cancer Institute. Monographs.

[11]  H. Rugo,et al.  NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[12]  Siu L. Hui,et al.  Survival, Chemotherapy Treatments, and Health Care Utilization Among Patients with Advanced Small Cell Lung Cancer: An Observational Study , 2019, Advances in Therapy.

[13]  Wanmei Ou,et al.  Temporal phenotyping by mining healthcare data to derive lines of therapy for cancer , 2019, J. Biomed. Informatics.

[14]  F. Jin,et al.  Chemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: A SEER‐Medicare study , 2019, Cancer medicine.

[15]  T. Owonikoko,et al.  Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Hushan Yang,et al.  Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Penrod,et al.  Adherence to recommended clinical guidelines in extensive disease small-cell lung cancer across the US, Europe, and Japan , 2019, Therapeutics and clinical risk management.

[18]  Xiaodong Yang,et al.  Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades , 2019, Cancer management and research.

[19]  D. Henry,et al.  Chemotherapy-induced anemia: etiology, pathophysiology, and implications for contemporary practice , 2018, International Journal of Clinical Transfusion Medicine.

[20]  C. Bokemeyer,et al.  Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines† , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  G. Otterson,et al.  Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis. , 2017, International journal of radiation oncology, biology, physics.

[22]  Michelle R. Brown,et al.  Adverse Reactions to Transfusion of Blood Products and Best Practices for Prevention. , 2017, Critical care nursing clinics of North America.

[23]  A. Bezjak,et al.  Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial , 2017, The Lancet. Oncology.

[24]  J. Li,et al.  Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages , 2017, Scientific Reports.

[25]  J. Li,et al.  Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages , 2017, Scientific Reports.

[26]  N. Rashid,et al.  Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system , 2016, Breast cancer.

[27]  K. Knopf,et al.  Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data. , 2016, Clinical lymphoma, myeloma & leukemia.

[28]  G. Aravantinos,et al.  Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia. , 2016, Molecular and clinical oncology.

[29]  J. Mardekian,et al.  Abstract B102: NSCLC observations combining medical charts and administrative claims data , 2015 .

[30]  Ting Chen,et al.  Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer. , 2015, International journal of radiation oncology, biology, physics.

[31]  J. Aerts,et al.  Comorbidity in Patients With Small-Cell Lung Cancer: Trends and Prognostic Impact. , 2015, Clinical lung cancer.

[32]  D. Kuter.  Managing thrombocytopenia associated with cancer chemotherapy. , 2015, Oncology.

[33]  J. Crawford,et al.  A review of relative dose intensity and survival in patients with metastatic solid tumors. , 2015, Critical reviews in oncology/hematology.

[34]  C. Rudin,et al.  Small cell lung cancer: Where do we go from here? , 2015, Cancer.

[35]  J. Barreto,et al.  Antineoplastic Agents and the Associated Myelosuppressive Effects , 2014, Journal of pharmacy practice.

[36]  Danielle E. Green,et al.  Consequences of irradiation on bone and marrow phenotypes, and its relation to disruption of hematopoietic precursors. , 2014, Bone.

[37]  R. Hubbard,et al.  Treatment decisions and survival for people with small-cell lung cancer , 2014, British Journal of Cancer.

[38]  D. de Ruysscher,et al.  Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  D. Addrizzo-Harris,et al.  Executive Summary: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[40]  T. Gauler,et al.  A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  M. Aapro,et al.  Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  L. Ek,et al.  Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  G. Lyman,et al.  Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  N. Hanna,et al.  Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  R. Marks,et al.  Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  J. Cedarbaum.  Survival , 2004 .

[47]  L. Balducci.  Myelosuppression and its consequences in elderly patients with cancer. , 2003, Oncology.

[48]  G. Lyman,et al.  Epidemiology of febrile neutropenia. , 2003, Supportive cancer therapy.

[49]  C. Klabunde,et al.  Overview of the SEER-Medicare Data , 2002 .

[50]  Deborah Schrag,et al.  Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population , 2002, Medical care.

[51]  K. Mori,et al.  Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. , 2002, The New England journal of medicine.

[52]  A. Coldman,et al.  Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  L. Einhorn,et al.  Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  J Sullivan,et al.  Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. , 1995, International journal of radiation oncology, biology, physics.

[55]  H. Barkley,et al.  Effects of brain irradiation and chemotherapy on myelosuppression in small-cell lung cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Martin S. Fridson,et al.  Trends , 1948, Bankmagazin.

[57]  F. Khuri,et al.  Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005 , 2016, Cancer.

[58]  J. Hay,et al.  Economic Burden of Haematological Adverse Effects in Cancer Patients , 2007, Clinical drug investigation.

[59]  G. Lyman.  Risks and consequences of chemotherapy-induced neutropenia. , 2006, Clinical cornerstone.

[60]  R. G. Lacsamana,et al.  Where do we go from here? , 1986, The Journal of the Florida Medical Association.